<<Back to PressReleases



Lisa McEvoy
Director of Marketing and Communications
American Association for Thoracic Surgery
+1 617-312-1740
lmcevoy@aats.org
www.aats.org

 

Surgery soon after clinical staging of non-small cell lung cancer reduces cancer progression and improves likelihood of cure

Week by week analysis of treatment records reveals significant cancer upstaging with each increasing progressive week from initial clinical staging to surgery, according to presentation at the AATS 98th Annual Meeting

 

SAN DIEGO – April 30, 2018 – Significant upstaging or reclassification to a more advanced stage due to cancer progression in non-small cell lung cancer (NSCLC) can occur with each successive week from initial clinical staging to surgery, according to data presented at the American Association for Thoracic Surgery’s 98th Annual Meeting. The same study showed that early intervention after completion of clinical staging leads to increased survival rates.

Clinical staging describes the severity of a patient’s cancer based on the magnitude of the primary tumor and the extent to which this cancer has spread. National Cancer Comprehensive Network (NCCN) guidelines recommend surgery within eight weeks of completed clinical staging for NSCLC. Surgery offers a chance for cure in approximately 15 percent of patients diagnosed with stage I NSCLC, but effective treatment requires accurate staging to guide effective management. Delay in surgery in clinical stage I is associated with increased upstaging and decreased survival.

“Our study evaluated the possibility of cancer upstaging using a more granular analysis, looking at the rates of upstaging for each progressive week from week one to week 12 for patients with stage I NSCLC,” explains Harmik J. Soukiasian, MD, Chief, Division of Thoracic Surgery, Cedars-Sinai Health System, Los Angeles, who led the study.

Investigators examined treatment data of over 52,000 clinical stage I NSCLC patients undergoing surgical resection from the National Cancer Data Base (NCDB). Patients who had anatomic lobar resection and lymphadenectomy or lymph node sampling, who did not receive pre-operative chemotherapy for clinical stage I NSCLC, were analyzed and compared to their eventual pathologic staging. The rates of upstaging for stage I tumors were evaluated based on the time from completed clinical staging to surgery for the first twelve weeks. Subgroup analyses were performed for IA and IB adenocarcinoma and squamous cell carcinoma.

Results showed overall survival improves with accurate staging in clinical stage I NSCLC. There was significant cancer upstaging with each progressive week from clinical staging to surgery, with a significant increase of upstaging to stage 3A at nine weeks, reinforcing the need for surgery within the NCCN guideline recommendation of eight weeks.


Caption: Results showed overall survival improves with accurate staging in clinical stage I NSCLC.

Upstaging was similar for both adenocarcinoma and squamous cell carcinoma. Stage IA upstages at a higher rate than IB.


Caption: Weekly upstaging by clinical stage shows a significant rate of weekly upstaging. Overall, stage IA (orange) upstages at a higher rate than IB (grey).

 “An astonishing number of clinical stage I NSCLC patients upstaged to 3A disease at the time of surgery. Interestingly, a higher proportion of both clinical IA and IB patients upstaged to 3A versus 2B, suggesting a possible need for more aggressive mediastinal staging, even in early-staged patients. Although current national guidelines recommend surgery within eight weeks from diagnosis, our study demonstrates there is a benefit in doing surgery even within a week to week basis,” concludes Dr. Soukiasian

 

Caption: Overall survival improves with early surgical resection in clinical stage I NSCLC.

 

#  #  #

 NOTES FOR EDITORS

“Effects of Time From Completed Clinical Staging to Surgery: Does it Make a Difference in Stage 1 Non-Small Cell Lung Cancer?” by Harmik J. Soukiasian, MD, Fernando Espinoza-Mercado, MD, Jerald Borgella, MD, David Berz, MD, PhD, and Taryne Imai, MD. Presented by Harmik J. Soukiasian, MD, at the AATS 98th Annual Meeting, April 28-May 1, 2018, San Diego, Calif., during the General Thoracic Surgery Simultaneous Session on Monday, April 30, 2018, 5:07-5:25 PM PT. The abstract for this presentation can be found at: http://aats.org/aatsimis/AATS/Meetings/Active_Meetings/98th_Annual_Meeting/Preliminary_Program/Abstracts/67.aspx

For more information or to reach the authors for comment, contact Lisa McEvoy, Director of Marketing and Communications for AATS at +1 617-312-1740 or lmcevoy@aats.org. Dr. Soukiasian may be reached directly at Harmik.Soukiasian@cshs.org or via Diane Wedner, Senior Communications Specialist, Cedars-Sinai, at +1 310-733-8604 (mobile), +1 310-248-6608 (office), or Diane.Wedner@cshs.org.

ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1400 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit www.aats.org to learn more.